<< Back
Nabi Biopharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference

ROCKVILLE, Md., Feb 7, 2011 (GlobeNewswire via COMTEX) --

Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that Dr. Raafat Fahim, President and Chief Executive Officer will present at the 13th Annual BIO CEO & Investor Conference on February 14 - 15, 2011 at the Waldorf Astoria Hotel in New York, NY. Dr. Fahim's presentation is scheduled for Tuesday, February 15, 2011 at 11:00 a.m., ET.

You can access the web cast of this presentation on the company's "Events and Webcasts" page at www.nabi.com or at http://www.veracast.com/webcasts/bio/ceoinvestor2011/16207411.cfm.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(R) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Nabi Biopharmaceuticals

CONTACT: Investor Relations
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Vaxart Inc's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.